Hanno

Bark extracts of Khaya senegalensis contain flavonoids, terpenoids, saponins, alkaloids, and tannins that exert antimicrobial, anti-inflammatory, and hepatoprotective effects by suppressing reactive oxygen species production and modulating antioxidant enzyme activity. In preclinical studies, bark fractions inhibited phagocyte oxidative burst by up to 70.7% at 6.25 µg/mL and synergistically restored catalase, superoxide dismutase, and glutathione levels in paracetamol-damaged rat hepatocytes at statistically significant levels (P<0.05, CDI<1).

Origin & History

Khaya senegalensis, commonly called African mahogany or 'Hanno' in Akan-speaking communities of West Africa, is a large deciduous tree native to the semi-arid Sahel and savanna zones stretching from Senegal and Gambia eastward through Ghana, Nigeria, and Sudan. It thrives in seasonally dry tropical climates with well-drained laterite soils, typically at elevations below 1,000 meters, and is often found along riverbanks and in open woodland. The tree is cultivated in agroforestry systems across sub-Saharan Africa both for its dense, durable timber and its extensive role in indigenous pharmacopoeias.

Historical & Cultural Context

In Akan-speaking communities of Ghana and neighboring West African nations, the tree known as 'Hanno' has been a cornerstone of traditional healing for generations, with bark decoctions prescribed by herbalists specifically for febrile illness attributed to malaria, as well as for wound infections and gastrointestinal complaints. Across the wider Sudano-Sahelian belt—spanning Senegal, Mali, Burkina Faso, and Nigeria—the species occupies a prominent place in diverse indigenous pharmacopoeias under names including 'Cailcédrat' in Francophone regions and 'Oganwo' in Yoruba practice, used for skin diseases, venereal infections, and liver complaints. Preparation methods have historically centered on cold-water infusions or prolonged bark decoctions, sometimes combined with other medicinal plants to achieve what traditional practitioners describe as potentiating effects, a practice partially corroborated by modern combination synergy studies with Entada africana. The timber's economic importance as African mahogany has paradoxically contributed to overharvesting pressures that threaten the very bark-producing trees upon which these medicinal traditions depend.

Health Benefits

- **Antimalarial and Antiparasitic Activity**: Bark extracts have been traditionally employed in Akan medicine for malaria treatment; phytochemicals including alkaloids and terpenoids are believed to interfere with parasite metabolic pathways, though controlled clinical validation remains pending.
- **Antimicrobial Action Against Tuberculosis**: Chloroform bark fractions demonstrated inhibition of Mycobacterium tuberculosis (H37Ra strain) at concentrations of 6.25–125 µg/mL in vitro without cytotoxicity to human monocyte-derived macrophages, suggesting hydrophobic secondary metabolites disrupt mycobacterial cell wall integrity.
- **Anti-Inflammatory Effects**: Bark and leaf extracts suppressed phagocyte oxidative burst (ROS production) by 67.1–70.7% in polymorphonuclear and mononuclear cells at 6.25 µg/mL, indicating potent modulation of the NADPH oxidase inflammatory pathway.
- **Hepatoprotective Properties**: Stem bark fractions synergistically restored catalase (CAT) and superoxide dismutase (SOD) activities, normalized glutathione (GSH) levels, and reduced malondialdehyde (MDA) and alanine aminotransferase (ALT) leakage in paracetamol-challenged rat hepatocytes, with combination drug interaction index (CDI) values below 1 indicating true synergy.
- **Antioxidant Activity**: Steroids, cardiac glycosides, flavonoids, and tannins identified in methanol bark extracts contribute to free radical scavenging capacity, with oxidative stress mitigation supported by enzyme upregulation data from animal models.
- **Broad-Spectrum Antibacterial Effects**: Secondary metabolites including flavonoids and terpenoids disrupt bacterial cell membranes across multiple pathogenic species, as demonstrated in disk diffusion and broth microdilution assays against common Gram-positive and Gram-negative pathogens.
- **Immunomodulatory Potential**: Suppression of reactive oxygen species in both polymorphonuclear neutrophils (PMNs) and mononuclear cells (MNCs) at low micromolar concentrations points to meaningful modulation of innate immune activation, relevant to inflammatory and infectious disease contexts.

How It Works

Flavonoids and terpenoids present in Khaya senegalensis bark extracts are believed to disrupt microbial and parasitic cell membrane integrity through hydrophobic interactions, while simultaneously chelating metal ions involved in Fenton-type ROS-generating reactions. Anti-inflammatory activity is mechanistically attributed to inhibition of NADPH oxidase in phagocytes, reducing superoxide anion output by up to 70.7% at 6.25 µg/mL, thereby blunting the oxidative burst characteristic of acute innate immune responses. Hepatoprotective synergy—demonstrated in paracetamol-injured rat hepatocyte models—operates through upregulation of endogenous antioxidant enzymes (catalase and superoxide dismutase) and replenishment of the glutathione pool, collectively reducing lipid peroxidation as measured by malondialdehyde and limiting hepatocellular leakage of ALT. No specific receptor-binding partners, kinase targets, or transcription factor interactions have been characterized at the molecular level; current mechanistic understanding derives entirely from in vitro assays and animal biomarker data rather than direct target engagement studies.

Scientific Research

The evidence base for Khaya senegalensis consists exclusively of in vitro cell culture studies and small animal experiments; no peer-reviewed human clinical trials with defined sample sizes, randomization, or effect sizes have been published as of the available literature. Key in vitro findings include 67.1–70.7% inhibition of phagocyte oxidative burst at 6.25 µg/mL and anti-Mycobacterium tuberculosis activity across a 6.25–125 µg/mL concentration range without macrophage cytotoxicity. Hepatoprotective outcomes in rodent models reached statistical significance (P<0.05) with CDI values below 1 for combination bark fraction formulations alongside Entada africana, though the translational relevance of these animal doses to human therapeutics is unknown. Bioassay-guided fractionation programs are ongoing to isolate and characterize individual active constituents, but results remain preclinical and no pharmacokinetic, bioavailability, or safety data from human subjects exist.

Clinical Summary

No human clinical trials have been conducted on Khaya senegalensis extracts in any formulation or indication, including its primary traditional use as an antimalarial in Akan medicine. All outcome data originate from in vitro assays—such as the 70.7% ROS inhibition in phagocytes—and rodent hepatoprotection models where antioxidant enzymes and liver injury biomarkers were measured under paracetamol challenge. Effect sizes from animal studies are statistically significant but cannot be extrapolated to human efficacious doses without pharmacokinetic bridging studies. Confidence in any clinical benefit is therefore very low; the ingredient is best characterized as a pharmacologically promising traditional remedy requiring rigorous human investigation.

Nutritional Profile

Khaya senegalensis bark is not consumed as a macronutrient source and does not contribute meaningfully to dietary protein, carbohydrate, or lipid intake. Its pharmacological relevance derives from a dense secondary metabolite profile: methanol bark extracts contain saponins, tannins, phlobatannins, flavonoids, terpenoids, alkaloids, cardiac glycosides, anthraquinones, aldehyde/carbonyl compounds, and reducing sugars, with the full complement present in methanol but subsets absent in ethanol and aqueous preparations. The essential oil fraction—characterized by GC/MS—is dominated by oleic acid (39.16%), octadecanoic acid/stearic acid (21.9%), cis-11-hexadecenal (18.88%), n-hexadecanoic acid/palmitic acid (12.08%), and minor components including dodecanoyl chloride (3.93%), 1-pentadecanol (1.84%), 13,16-octadecadienoic acid methyl ester (1.71%), and sulfurous acid decylpentyl ester (0.51%). Bioavailability of these compounds in oral human consumption is entirely uncharacterized; lipophilic terpenoids and flavonoid aglycones are generally expected to have moderate-to-poor oral bioavailability without formulation optimization.

Preparation & Dosage

- **Aqueous Decoction (Traditional)**: Bark pieces boiled in water for 20–40 minutes; consumed as a tea-like preparation in volumes of approximately 200–400 mL; dose unquantified and unstandardized in ethnopharmacological records.
- **Ethanol or Methanol Bark Extract (Research-Grade)**: Used in in vitro studies at concentrations of 6.25–125 µg/mL; no equivalent oral human dose established; extractions performed by maceration or Soxhlet apparatus.
- **Chloroform Fraction (Anti-TB Research)**: Hydrophobic fraction isolated via sequential solvent partitioning; active at 6.25–125 µg/mL against M. tuberculosis in vitro; no human dose equivalent available.
- **Essential Oil (GC/MS Characterized)**: Obtained via methanol-chloroform co-extraction; characterized for fatty acid composition; no therapeutic dosing established for human use.
- **No Standardized Commercial Supplement Form Exists**: There is no currently marketed capsule, tablet, or tincture with defined extract ratio or marker compound standardization; preparations remain at traditional or research levels only.
- **Timing and Duration**: Completely undefined; traditional use frequency varies by region and practitioner; no clinical guidance available.

Synergy & Pairings

Preclinical evidence demonstrates that Khaya senegalensis stem bark fractions combined with Entada africana produce synergistic hepatoprotection in rodent models, with a combination drug interaction index (CDI) below 1 indicating effects greater than additive for restoration of CAT, SOD, and GSH levels while reducing MDA and ALT leakage. The mechanism of this synergy is hypothesized to involve complementary antioxidant enzyme upregulation pathways—with each plant fraction targeting different aspects of the oxidative stress cascade—though molecular-level confirmation is lacking. Given the overlapping flavonoid and terpenoid content, co-administration with other polyphenol-rich botanical extracts such as green tea catechins or quercetin-containing supplements is theoretically plausible for additive NADPH oxidase inhibition, but no direct experimental data support this combination.

Safety & Interactions

In vitro cytotoxicity testing of the chloroform bark fraction against human monocyte-derived macrophages demonstrated no toxic effects at concentrations sufficient for antimycobacterial activity (6.25–125 µg/mL), providing a limited but encouraging safety signal at the cellular level. No human adverse event data, drug interaction profiles, or contraindication data exist in the published literature, meaning that safety in clinical populations—including those with hepatic impairment, renal insufficiency, or polypharmacy—cannot be assessed. The presence of cardiac glycosides in bark extracts warrants caution in patients using digoxin or other cardioactive medications, as additive electrophysiological effects are theoretically possible. No guidance exists for use in pregnancy or lactation, and in the absence of human safety data, use in these populations should be avoided; maximum safe doses for human consumption have not been established.